Editing Daiichi Sankyo Company, Limited
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 121: | Line 121: | ||
=== Dato-DXd === | === Dato-DXd === | ||
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on a variety of epithelial tumours and correlates with a poor prognosis, Dato-DXd is being developed as a novel TROP2-directed ADC. Dato-DXd demonstrated potent antitumor activity against TROP2-expressing tumors via efficent payload delivery into tumors alongside acceptable safety profiles in preclinical models, suggesting Dato-DXd could be a valuable treatment | Trophoblast cell surface antigen 2 (TROP2) is highly expressed on a variety of epithelial tumours and correlates with a poor prognosis, Dato-DXd is being developed as a novel TROP2-directed ADC. Dato-DXd demonstrated potent antitumor activity against TROP2-expressing tumors via efficent payload delivery into tumors alongside acceptable safety profiles in preclinical models, suggesting Dato-DXd could be a valuable treatment. | ||
Daiichi Sankyo has a variety of Dato-DXd products currently in different phases of clinical trials: | Daiichi Sankyo has a variety of Dato-DXd products currently in different phases of clinical trials: | ||
Line 190: | Line 190: | ||
=== 3ADC Conclusion === | === 3ADC Conclusion === | ||
In conclusion, Daiichi Sankyo is developing a '''wide range''' of '''cancer-targeting drugs''', with a primary focus on breast | In conclusion, Daiichi Sankyo is developing a '''wide range''' of '''cancer-targeting drugs''', with a primary focus on breast cancer, with Dato-DXds targeting hormone receptor positive, HER2 low or HER2 negative breast cancer, and triple negative breast cancer. T-DXds (such as ENHERTU®) targeting HER2 positive breast cancer, particularly when a patient has received prior anti-HER2 treatment. HER3-DXds targeting EFGR-positive NSCLC, and particularly in cases where the patient has become resistant to first-line treatments (such as EGFR TKIs). | ||
== Leadership == | == Leadership == | ||
Line 631: | Line 631: | ||
# AstraZeneca PLC, Market Cap - $169.1B -Pharmaceutical company focused on medications for respiratory, cardiovascular, oncology, and other therapeutic areas, competes with Daiichi Sankyo in cardiovascular drugs and oncology treatments. | # AstraZeneca PLC, Market Cap - $169.1B -Pharmaceutical company focused on medications for respiratory, cardiovascular, oncology, and other therapeutic areas, competes with Daiichi Sankyo in cardiovascular drugs and oncology treatments. | ||
# GlaxoSmithKline (GSK), Market Cap - $57.3B -Multinational pharmaceutical company developing pharmaceutical products, vaccines, and consumer healthcare products. | # GlaxoSmithKline (GSK), Market Cap - $57.3B -Multinational pharmaceutical company developing pharmaceutical products, vaccines, and consumer healthcare products. | ||
'''Technical Analysis''' | |||
== Catalysts == | == Catalysts == |